Journal profile · Medicine-Hematology
Hematology/ Oncology and Stem Cell Therapy
ISSN 1658-3876 · eISSN 2589-0646 · Elsevier · Netherlands
Hematology/ Oncology and Stem Cell Therapy: diamond open access (no APC); no APC; median 124 days to acceptance (36 articles, last 24 months); 22 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Hematology/ Oncology and Stem Cell Therapy is published by Elsevier. By OpenAlex counts of its recent articles, its largest topics are Hematopoietic Stem Cell Transplantation, Lymphoma Diagnosis and Treatment and Acute Myeloid Leukemia Research, together about 35.8% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Research area (LetPub): Medicine-Hematology
Editor-in-chief Mahmoud AljurfPublisher website
Editorial board by country: none in mainland China; most named Saudi Arabia 4 (4 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Hematopoietic Stem Cell TransplantationMedicine17.4%
- Lymphoma Diagnosis and TreatmentMedicine9.9%
- Acute Myeloid Leukemia ResearchMedicine8.6%
- Chronic Lymphocytic Leukemia ResearchMedicine4.9%
- Hemoglobinopathies and Related DisordersMedicine4.4%
- Multiple Myeloma Research and TreatmentsMedicine4.4%
- Acute Lymphoblastic Leukemia researchMedicine4.3%
- Hematological disorders and diagnosticsMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Hematology | Q2 | 53/151 | 65th |
| Oncology | Q2 | 207/428 | 51st |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 4.2LetPub ·
- CiteScore (publisher)
- 4.2Publisher website ·
- SJR 2026-06
- 0.51LetPub ·
- SNIP 2026-06
- 0.56LetPub ·
- h-index
- 40OpenAlex ·
- i10-index
- 288OpenAlex ·
- 2-year mean citedness
- 1.04OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 818 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 12 | 12 | 573 |
| 2025 | 22 | 22 | 844 |
| 2024 | 21 | 21 | 978 |
| 2023 | 36 | 36 | 984 |
| 2022 | 12 | 12 | 1,103 |
| 2021 | 49 | 49 | 1,114 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
124 daysMedian, submission to acceptance · P25–P75 67 days – 210 days
- Acceptance to online
- median 57 days (37 articles)
- Submission to online
- median 199 days
- Sample
- 36 articles with submission and acceptance dates (37 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 27 weeksLetPub ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY-NC-SA | |
| LetPub | No APC | No | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Netherlands
- Language
- English
- ISSN
- 1658-3876
- Electronic ISSN
- 2589-0646
- Latest issue on the website
- Volume 19, Issue 1 (March 2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Hematology/ Oncology and Stem Cell Therapy
How long does peer review take at Hematology/ Oncology and Stem Cell Therapy?
Based on the dates recorded on 36 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 124 days (interquartile range 67–210 days); authors report an average review time of about 27 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Hematology/ Oncology and Stem Cell Therapy based?
Of the 4 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Saudi Arabia (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Hematology/ Oncology and Stem Cell Therapy?
According to LetPub and DOAJ records, Hematology/ Oncology and Stem Cell Therapy is indexed in Scopus and DOAJ.
Is Hematology/ Oncology and Stem Cell Therapy open access, and what is the APC?
Hematology/ Oncology and Stem Cell Therapy is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .